

Three New C₁₉-Diterpenoid Alkaloids from *Aconitum hemsleyanum* var. *circinatum*


by Feng Gao^{a)}), Xiao-Yu Liu^{b)}, and Feng-Peng Wang^{*b)}

^{a)} Agronomy College, Sichuan Agricultural University, No. 46 Xinkang Road, Yaan 625014, P. R. China

^{b)} Department of Chemistry of Medicinal Natural Products, West China College of Pharmacy, Sichuan University, No. 17, Duan 3, Renmin Nan Road, Chengdu 610041, P. R. China
(phone/fax: +86-28-5501368; e-mail: wfp@scu.edu.cn)

Further phytochemical investigation of the roots of *Aconitum hemsleyanum* var. *circinatum* resulted in the isolation of three new aconitine-type C₁₉-diterpenoid alkaloids, hemsleyanines E–G (**1–3**, resp.). The structures of these new alkaloids were elucidated on the basis of spectral data including 2D-NMR.

Introduction. – There is a long and fascinating history of the utilization of the plants of *Aconitum* and *Delphinium* as a source of medicinal drugs by various civilizations. *Aconitum* preparations have been used as cardiotonics, febrifuges, sedatives, and anodynes, while *Delphinium* extracts have also been employed as sedatives and anthelmintics [1]. The diterpenoid alkaloids are considered to be the main bioactive components in these plants. In the course of our continuing investigation on the species of *Aconitum* and *Delphinium* [2–5], we studied the roots of *A. hemsleyanum* var. *circinatum* [6–8], which is endemic to the Emei Mountains of Sichuan Province in China and has been used as a folk remedy for the treatment of arthritic pain in Chinese traditional herbs [9]. Based on the isolation of 20 C₁₉-diterpenoid alkaloids from this plant [6–8], an additional phytochemical investigation was carried out, which led to the isolation of three new aconitine-type C₁₉-diterpenoid alkaloids, designated as hemsleyanines E–G (**1–3**, resp.). Herein, we report the isolation and structure elucidation of these new alkaloids.



Results and Discussion. – Hemsleyanine E (**1**) was isolated as an amorphous powder. The molecular formula C₃₀H₄₁NO₉ was deduced from the [M + H]⁺ signal in

the HR-FAB-MS (m/z 560.2875; calc. 560.2860) and the ^{13}C -NMR data (*Table*). The ^1H - and ^{13}C -NMR spectra of **1** exhibited characteristic NMR features of an aconitine-type C_{19} -diterpenoid alkaloid [10], bearing three MeO groups ($\delta(\text{H})$ 3.26, 3.32, 3.40 (3s); $\delta(\text{C})$ 55.7, 58.1, 59.4 (3q)), and an anisoyl ester ($\delta(\text{H})$ 6.90, 7.97 (2d, $J = 8.4$, each 2 H), $\delta(\text{H})$ 3.84 (s, 3 H); $\delta(\text{C})$ see *Table*), but lacking the typical *N*-ethyl group. The doublet ($J = 8.4$ Hz) at $\delta(\text{H})$ 5.16 in the ^1H -NMR spectrum could be assigned to the H_β -C(14) based on the multiplicity and the coupling constant, resulting in the location of the anisoyl ester group at C(14) [10]. Three MeO groups could be located at C(1), C(16), and C(18), respectively, according to the HMBCs (*Fig. 1*) between 1-MeO ($\delta(\text{H})$ 3.26) and C(1) ($\delta(\text{C})$ 82.1), 16-MeO ($\delta(\text{H})$ 3.40) and C(16) ($\delta(\text{C})$ 83.0), as well as 18-MeO ($\delta(\text{H})$ 3.32) and C(18) ($\delta(\text{C})$ 78.0). Comparison of the NMR spectra of **1** with those of hemsleyadine (**4**) [6], whose structure was confirmed by single crystal X-ray analysis, showed that the latter had an additional *N*-ethyl group. The ^{13}C -NMR data of **1** and **4** are very similar except for C(7), C(17), and C(19) (*Table*), which could be contributed to the effect of *N*-deethylation. The structure of hemsleyanine E, therefore, was established as **1** by careful analysis of the ^1H -, ^{13}C -NMR, and 2D-NMR (^1H , ^1H -COSY, HMQC, and HMBC) spectra. Hemsleyanine E (**1**) is a rare C_{19} -diterpenoid alkaloid containing a 5β -OH group, and without *N*-ethyl group.




Fig. 1. Selected ^1H , ^1H -COSY and HMBC correlations of hemsleyanine E (**1**)

Hemsleyanine F (**2**), a white amorphous compound, had a molecular formula of $\text{C}_{31}\text{H}_{41}\text{NO}_9$ (m/z 571.2662; calc. 571.2781) derived from the HR-EI-MS. The NMR spectra of **2** showed an *N*-ethyl group ($\delta(\text{H})$ 1.09 (*t*, $J = 7.2$, 3 H), 2.40–2.44, 2.46–2.49 (2*m*, 1 H each); $\delta(\text{C})$ 13.5 (*q*), 48.5 (*t*)), two MeO groups ($\delta(\text{H})$ 3.34, 3.43 (2*s*, each 3 H); $\delta(\text{C})$ 58.3, 59.5 (2*q*)), and an anisoyl ester ($\delta(\text{H})$ 6.89, 7.92 (2*d*, $J = 8.8$, each 2 H), $\delta(\text{H})$ 3.83 (*s*, 3 H); $\delta(\text{C})$ see *Table*), which strongly suggested an aconitine-type C_{19} -diterpenoid alkaloid for **2** [10]. The anisoyl ester group could also be located at C(14) due to the one-H-atom doublet signal ($J = 4.8$ Hz) at $\delta(\text{H})$ 5.19 in the ^1H -NMR spectrum. Comparison of the NMR data of **2** with those of the known hemsleyadine (**4**) revealed that the latter had an additional MeO group but the former had a quaternary C-atom at $\delta(\text{C})$ 212.2, whose HMBCs (*Fig. 2*) between H-C(2) ($\delta(\text{H})$ 2.40–2.44, 3.24–3.28) and H-C(3) ($\delta(\text{H})$ 1.70–1.74, 2.43–2.47) indicated that the two compounds are very similar only except for the substituents at C(1): hemsleyanine F contains an oxo group at C(1) instead of MeO. Therefore, the structure of hemsleyanine F was assigned as **2**. This structure was also confirmed by extensive analysis of its 2D-

Table. ¹H- and ¹³C-NMR Data of Compound 4. δ in ppm, J in Hz.

	1		2		3		4	
	δ(H)	δ(C)	δ(H)	δ(C)	δ(H)	δ(C)	δ(H)	δ(C)
H-C(1)	3.24–3.28 (m, H _β)	82.1 (d)	–	212.2 (s)	3.22–3.26 (m, H _β)	83.6 (d)	–	83.3
CH ₂ (2)	1.75–1.78 (m, H _α), 2.15–2.21 (m, H _β)	25.0 (t)	2.40–2.44 (m, H _α), 3.24–3.28 (m, H _β)	40.9 (t)	2.00–2.04 (m, H _α), 2.05–2.09 (m, H _β)	26.2 (t)	–	25.7
CH ₂ (3)	1.38–1.42 (m, H _α), 2.10–2.15 (m, H _β)	26.4 (t)	1.70–1.74 (m, H _α), 2.43–2.47 (m, H _β)	31.7 (t)	1.35–1.38 (m, H _α), 1.70–1.74 (m, H _β)	–	–	27.9
C(4)	–	41.3 (s)	–	41.2 (s)	–	–	–	40.8
C(5)	–	82.8 (s)	–	88.8 (s)	–	–	–	83.8
CH ₂ (6)	1.78–1.82 (m, H _α), 2.17–2.20 (m, H _β)	34.8 (t)	1.80–1.85 (m, H _α), 2.13–2.16 (m, H _β)	34.2 (t)	1.85–1.89 (m, H _α), 2.20–2.24 (m, H _β)	–	–	34.2
H-C(7)	1.90–1.93 (m, H _β)	51.7 (d)	2.10 (br. s, H _β)	47.1 (d)	2.50–2.54 (m, H _β)	–	–	45.4
C(8)	–	74.2 (s)	–	74.6 (s)	–	–	–	73.4
H-C(9)	2.75 (dd, J = 9.6, 4.4, H _β)	45.7 (d)	2.76 (t, J = 5.2, H _β)	45.9 (d)	2.84 (dd, J = 9.6, 4.8, H _β)	–	–	46.8
H-C(10)	2.57–2.61 (m, H _β)	35.8 (d)	2.17–2.20 (m, H _β)	31.6 (d)	2.40–2.45 (m, H _β)	–	–	36.3
C(11)	–	50.7 (s)	–	63.5 (s)	–	–	–	50.2
CH ₂ (12)	1.99–2.02 (m, H _β), 2.08–2.12 (m, H _α)	34.9 (t)	1.33–1.38 (m, H _β), 2.60–2.64 (m, H _α)	39.3 (t)	2.00–2.04 (m, H _β), 2.05–2.09 (m, H _α)	–	–	35.7
C(13)	–	76.1 (s)	–	75.9 (s)	–	–	–	76.3
H-C(14)	5.16 (d, J = 4.8, H _β)	79.8 (d)	5.19 (d, J = 4.8, H _β)	80.0 (d)	5.24 (d, J = 4.8, H _β)	–	–	80.1
CH ₂ (15) or	2.27–2.31 (m, H _α), 2.63–2.66 (m, H _β)	41.8 (t)	2.32–2.35 (m, H _α), 2.50–2.54 (m, H _β)	43.0 (t)	5.56 (d, J = 9.6)	–	–	41.0
H-C(16)	3.32–3.36 (m, H _α)	83.0 (d)	3.28–3.32 (m, H _β)	83.2 (d)	–	–	–	83.5
H-C(17)	3.12 (br. s)	58.3 (d)	2.90 (br. s)	64.6 (d)	3.01 (br. s)	–	–	63.0
CH ₂ (18)	2.98 (AB, J = 9.2), 3.58 (AB, J = 9.2), 2.48 (d, J = 10.2), 2.60 (hidden)	78.0 (t)	3.12 (AB, J = 9.6), 3.66 (AB, J = 9.6), 2.18 (hidden), 2.73 (hidden)	77.5 (t)	2.98 (AB, J = 11.2), 3.68 (AB, J = 11.2), 2.42 (hidden), 2.86 (hidden)	–	–	78.3
CH ₂ (19)	–	50.4 (t)	2.46–2.49 (m), 1.09 (t, J = 7.2)	56.5 (t)	5.90 (d, J = 9.6)	–	–	55.1
CH ₂ (21)	–	–	–	48.5 (t)	3.68 (AB, J = 11.2), 2.63–2.68 (m), 1.00 (t, J = 7.2)	–	–	48.7
Me(22)	–	–	–	13.5 (q)	–	–	–	13.2
1-MeO	3.26 (s)	55.7 (q)	–	–	3.24 (s)	–	–	56.0
16-MeO	3.40 (s)	58.1 (q)	3.43 (s)	58.3 (q)	–	–	–	57.8
18-MeO	3.32 (s)	59.4 (q)	3.34 (s)	59.5 (q)	–	–	–	59.1
ArC=O	–	166.4 (s)	–	166.2 (s)	–	–	–	166.5
C(1')	–	122.4 (s)	–	122.5 (s)	–	–	–	121.8
H-C(2',6')	7.97 (d, J = 8.4)	131.7 (d)	7.92 (d, J = 8.8)	131.8 (d)	7.80 (d, J = 8.8)	–	–	131.3
H-C(3',5')	6.90 (d, J = 8.4)	113.5 (d)	6.89 (d, J = 8.8)	113.6 (d)	6.90 (d, J = 8.8)	–	–	113.2
C(4')	–	163.2 (s)	–	163.4 (s)	–	–	–	163.8
4'-MeO	3.84 (s)	55.2 (q)	3.83 (s)	55.3 (q)	3.84 (s)	–	–	54.9

 a) Recorded in CDCl₃, ¹H-NMR at 400 MHz, and ¹³C-NMR at 100 MHz.




Fig. 2. Selected $^1\text{H},^1\text{H}$ -COSY and HMBC correlations of hemsleyanine F (**2**)

NMR ($^1\text{H},^1\text{H}$ -COSY, HMQC, and HMBC) spectra (Table). Hemsleyanine F (**2**) is an unusual natural C_{19} -diterpenoid alkaloid with an oxo group at C(1).

Hemsleyanine G (**3**), with a molecular formula of $\text{C}_{31}\text{H}_{41}\text{NO}_8$ (according to the HR-EI-MS), also exhibited characteristic NMR spectral features of a C_{19} -diterpenoid alkaloid containing an *N*-Et group ($\delta(\text{H})$ 1.00 (*t*, $J = 7.2$, 3 H), 2.30–2.34, 2.63–2.68 (*m*, 1 H each); $\delta(\text{C})$ 13.4 (*q*), 49.0 (*t*), two MeO groups ($\delta(\text{H})$ 3.24, 3.33 (*s*, each 3 H); $\delta(\text{C})$ 56.4 (*q*), 59.5 (*q*), an anisoyl ester group ($\delta(\text{H})$ 6.90, 7.80 (*d*, $J = 8.8$, each 2 H), $\delta(\text{H})$ 3.84 (*s*, 3 H); $\delta(\text{C})$ see Table), and a disubstituted (*Z*)-C=C bond ($\delta(\text{H})$ 5.56, 5.90 (*d*, $J = 9.6$, each 1 H); $\delta(\text{C})$ 130.1, 135.0 (*2d*). Two MeO groups could be located at C(1) and C(18) due to the correlations between 1-MeO ($\delta(\text{H})$ 3.24) and C(1) ($\delta(\text{C})$ 83.6) and between 18-MeO ($\delta(\text{H})$ 3.33) and C(18) ($\delta(\text{C})$ 79.1) in the HMBC experiment (Fig. 3). On the other hand, a doublet at $\delta(\text{H})$ 5.24 ($J = 4.8$ Hz) could be attributed to H_β -C(14), implying the presence of the anisoyl group at C(14). The disubstituted C=C bond was located between C(15) and C(16) mainly based on the presence of critical HMBCs from H-C(15) ($\delta(\text{H})$ 5.56 (*d*, $J = 9.6$)) to C(7) ($\delta(\text{C})$ 41.2), C(8) ($\delta(\text{C})$ 74.3), C(9) ($\delta(\text{C})$ 46.1), and C(13) ($\delta(\text{C})$ 77.3), as well as H-C(16) ($\delta(\text{H})$ 5.90 (*d*, $J = 9.6$)) to C(8) ($\delta(\text{C})$ 74.3), C(13) ($\delta(\text{C})$ 77.3), and C(14) ($\delta(\text{C})$ 81.2). Finally, unambiguous assignments of ^1H - and ^{13}C -chemical shifts for hemsleyanine G (**3**) (Table) were accomplished using the 2D-NMR techniques ($^1\text{H},^1\text{H}$ -COSY, HMQC, and HMBC). All available evidence suggested the structure of hemsleyanine G as **3**.




Fig. 3. Selected $^1\text{H},^1\text{H}$ -COSY and HMBC correlations of hemsleyanine G (**3**)

This research work was financially supported by the National Natural Science Foundation of China (Nos. 30672526 and 30873147).

Experimental Part

General. Silica gel GF_{254} and H (Qindao Sea Chemical Factory, P. R. China) were used for TLC and column chromatography (CC), resp.; spots on TLC were detected with modified Dragendorff's reagent. A polyvinyl sulfonic ion exchange resin (H-form, cross linking 1×1 , Chemical Factory of Nankai University, P. R. China) was used for the extraction of total alkaloids. M.p.: thermal values analysis with microscope; uncorrected. Optical rotations: Perkin-Elmer 341 polarimeter. IR Spectra: Nicolet FT-IR 200SXY spectrophotometer. ^1H - and ^{13}C -NMR spectra: Varian Unity INOVA 400/54 NMR spectrometer in CDCl_3 with TMS as the internal standard. ESI- and HR-MS: VG Auto spec 3000 or Finnigan MAT 90 instrument.

Plant Material. The sample of *A. hemsleyanum* var. *circinatum* W. T. WANG was collected in the Emei Mountains, Sichuan Province, China, and authenticated by Prof. W. T. Wang from the Institute of Botany, Chinese Academy of Sciences, where a voucher specimen has been deposited.

Extraction and Isolation. The powdered roots (4.0 kg) of *A. hemsleyanum* var. *circinatum* were percolated with 0.05M HCl (40 l). Wet resin (dry weight 40 kg) was added to the percolate, followed by repeated washing on a suction filter with deionized H_2O . The air-dried resin was then alkalized with 10% aq. NH_4OH (1.8 l) and continuously extracted with Et_2O (5.0 l), and evaporated to give the total crude alkaloids (68.0 g) as yellowish amorphous powder. The crude alkaloids (38.2 g) were chromatographed on a SiO_2 column eluting with $\text{CHCl}_3/\text{MeOH}$ 200 : 1 \rightarrow 7 : 1 gradient system to give *hemsleyadine* (**4**; 2.6 g) and fractions *A* (3.2 g), *B* (10.8 g), *C* (9.6 g), and *D* (6.2 g). *Fr. B* (10.8 g) was chromatographed on a SiO_2 column eluting with $\text{CHCl}_3/\text{MeOH}$ 97 : 3 to afford fractions *B-1* (420 mg), *B-2* (1.2 g), *B-3* (4.2 g), and *B-4* (3.8 g). *Fr. B-2* was separated on a SiO_2 column eluting with petroleum ether (PE)/ Me_2CO 3 : 1 to give three subfractions *B-2-1* (120 mg), *B-2-2* (400 mg), and *B-2-3* (700 mg). Further SiO_2 chromatography of fraction *B-2-1* eluting with cyclohexane/ Me_2CO (3 : 1) produced *hemsleyanine G* (**3**, 82 mg). *Fr. B-4* was chromatographed over a SiO_2 column with PE/ Me_2CO 2 : 1 to give fractions *B-4-1* (1.2 g) and *B-4-2* (1.6 g). CC of *Fr. B-4-2* with cyclohexane/ $\text{Me}_2\text{CO}/\text{Et}_2\text{NH}$ 80 : 20 : 1 as eluent gave fractions *B-4-2-1* (76 mg), *B-4-2-2* (180 mg), and *B-4-2-3* (560 mg). In addition, *Fr. B-4-2-3* was chromatographed on a SiO_2 column (PE/ $\text{Me}_2\text{CO}/\text{Et}_2\text{NH}$ 80 : 20 : 1) to provide *hemsleyanine F* (**2**; 77 mg). Further SiO_2 chromatography of *Fr. D* eluting with $\text{CHCl}_3/\text{MeOH}$ 96 : 4 gave *hemsleyanine E* (**1**; 103 mg).

Hemsleyanine E (= (1 α ,7 β ,14 α ,16 β)-5,8,13-Trihydroxy-1,16-dimethoxy-4-(methoxymethyl)aconitan-14-yl 4-Methoxybenzoate; **1**). White amorphous powder. M.p. 81–82°. $[\alpha]_{\text{D}}^{20} = +60.2$ ($c = 1.0$, CHCl_3). IR (KBr): 3447, 2928, 1701, 1606, 1512, 1459, 1102. ^1H - (400 MHz, CDCl_3) and ^{13}C -NMR (100 MHz, CDCl_3): Table. ESI-MS: 560 (100, $[M + \text{H}]^+$). HR-FAB-MS: 560.2875 ($[M + \text{H}]^+$, $\text{C}_{30}\text{H}_{42}\text{NO}_8^+$; calc. 560.2860).

Hemsleyanine F (= (7 β ,14 α ,16 β)-20-Ethyl-5,8,13-trihydroxy-16-methoxy-4-(methoxymethyl)-1-oxo-aconitan-14-yl 4-Methoxybenzoate; **2**). White amorphous powder. M.p. 83–84°. $[\alpha]_{\text{D}}^{20} = -44.3$ ($c = 1.0$, CHCl_3). IR (KBr): 3443, 2938, 1699, 1615, 1503. ^1H - (400 MHz, CDCl_3) and ^{13}C -NMR (100 MHz, CDCl_3): Table. ESI-MS: 518 (100, $[M + \text{H}]^+$). HR-EI-MS: 571.2662 (M^+ , $\text{C}_{31}\text{H}_{41}\text{NO}_8^+$; calc. 571.2781).

Hemsleyanine G (= (1 α ,7 β ,14 α)-20-Ethyl-5,8,13-trihydroxy-1-methoxy-4-(methoxymethyl)aconit-15-en-14-yl 4-Methoxybenzoate; **3**). White amorphous powder. M.p. 87–88°. $[\alpha]_{\text{D}}^{20} = +63.3$ ($c = 1.0$, CHCl_3). ^1H - (400 MHz, CDCl_3) and ^{13}C -NMR (100 MHz, CDCl_3): Table. ESI-MS: 556 (100, $[M + \text{H}]^+$). HR-EI-MS: 555.2695 (M^+ , $\text{C}_{31}\text{H}_{41}\text{NO}_8^+$; calc. 555.2832).

REFERENCES

- [1] S. W. Pelletier, N. V. Mody, B. S. Joshi, L. C. Schramm, in 'Alkaloids: Chemical and Perspectives', Ed. S. W. Pelletier, Wiley, New York, 1983, Vol. 1, p. 153.
- [2] P. Tang, Q.-H. Chen, F.-P. Wang, *Tetrahedron Lett.* **2009**, 50, 460.
- [3] F.-Z. Chen, D.-L. Chen, Q.-H. Chen, F.-P. Wang, *J. Nat. Prod.* **2009**, 72, 18.
- [4] H. Yan, D.-L. Chen, X.-X. Jian, F.-P. Wang, *Helv. Chim. Acta* **2007**, 90, 1133.
- [5] X.-Y. Liu, Q.-H. Chen, F.-P. Wang, *Helv. Chim. Acta* **2009**, 92, 745.
- [6] F. Gao, F.-P. Wang, *Heterocycles* **2005**, 65, 365.
- [7] F. Gao, D.-L. Chen, F.-P. Wang, *Chem. Pharm. Bull.* **2006**, 54, 117.
- [8] F. Gao, Q.-H. Chen, F.-P. Wang, *J. Nat. Prod.* **2007**, 70, 876.

- [9] Institute of Botany, Chinese Academy of Sciences and Institute of Materia Medica, Chinese Academy of Medical Sciences, in 'Flora Republicae Popularis Sinicae', Science Press, Beijing, 1979, Vol. 27, p. 235.
- [10] S. W. Pelletier, N. V. Mody, B. S. Joshi, L. C. Schramm, in 'Alkaloids: Chemical and Perspectives', Ed. S. W. Pelletier, Wiley, New York, 1984, Vol. 2, p. 205.

Received September 21, 2009